What is the appropriate workup for suspected metabolic dysfunction‑associated steatotic liver disease (MASLD)?

Workup for Suspected MASLD

Use a two-step sequential approach: start with FIB-4 blood-based scoring, followed by liver elastography (transient elastography or MRE) to assess fibrosis stage, which is the key determinant of prognosis and management. 1, 2

Who Should Be Evaluated

Target case-finding (not universal screening) to high-risk populations 1, 2:

• Type 2 diabetes (strongest indication)
• Abdominal obesity PLUS ≥1 additional metabolic risk factor (hypertension, dyslipidemia, prediabetes)
• Persistently abnormal liver enzymes (ALT/AST)
• Radiological evidence of hepatic steatosis on imaging done for other reasons

Step 1: Initial Assessment

Confirm Steatosis

• Imaging detection: Ultrasound, CT, or MRI showing hepatic steatosis 3
• Document presence of ≥1 cardiometabolic risk factor to meet MASLD criteria 1

Exclude Other Causes

• Alcohol history: Must be <140 g/week for women, <210 g/week for men 2
• Rule out: viral hepatitis, drug-induced liver disease (corticosteroids, tamoxifen, methotrexate), hemochromatosis, autoimmune hepatitis 4

Assess Metabolic Risk Factors 1

Document presence of:

• Abdominal obesity (waist circumference or BMI)
• Type 2 diabetes or prediabetes
• Hypertension
• Elevated triglycerides
• Low HDL cholesterol

Step 2: Fibrosis Risk Stratification (Critical for Prognosis)

First-Line: FIB-4 Score

Calculate FIB-4 using: age, AST, ALT, platelet count 1, 2

Interpretation 2:

• FIB-4 <1.3: Low risk—manage in primary care, reassess annually
• FIB-4 1.3-2.67: Intermediate risk—proceed to Step 3 (elastography)
• FIB-4 >2.67: High risk—refer to hepatology

Important caveat: FIB-4 has age-dependent accuracy; may overestimate fibrosis in patients >65 years and underestimate in those <35 years 2

Second-Line: Liver Elastography

If FIB-4 is indeterminate or in high-risk groups 1, 2:

Vibration-Controlled Transient Elastography (VCTE) 2:

• <8.0 kPa: Low probability of advanced fibrosis—continue primary care management
• ≥8.0 kPa: Suggests advanced fibrosis—refer to hepatology

Alternative: MR elastography (MRE) has higher accuracy but limited availability 5

Alternative to Elastography

Enhanced Liver Fibrosis (ELF) test: Collagen-based blood biomarker panel can substitute for imaging when elastography unavailable 1, 2

Step 3: Additional Risk Stratification

Blood Biomarkers

• Standard liver enzymes (ALT/AST) alone are insufficient for fibrosis detection 1, 2
• Blood-based scores are better for ruling out advanced fibrosis
• Elastography is superior for ruling in advanced fibrosis 1, 2

Cardiovascular Risk Assessment

Essential because cardiovascular disease is the leading cause of death in MASLD, not liver disease 4, 6:

• Lipid panel
• Blood pressure
• Hemoglobin A1c
• 10-year cardiovascular risk calculation

When Liver Biopsy Is Needed

Biopsy is NOT required for most patients 1, 2. Consider only when:

• Diagnostic uncertainty (need to confirm steatohepatitis vs. simple steatosis)
• Ruling out alternative/coexisting liver diseases
• Enrollment in clinical trials
• Non-invasive tests are discordant

Critical limitation: Non-invasive tests cannot assess inflammation or hepatocyte ballooning—only biopsy can definitively diagnose MASH 1, 2

Surveillance Strategy

For Low-Risk Patients (FIB-4 <1.3)

• Reassess FIB-4 every 1-3 years 2
• Intensify metabolic comorbidity management

For Intermediate/High-Risk Patients

• Hepatology referral for comprehensive evaluation 2
• Surveillance for hepatocellular carcinoma if cirrhosis present
• Portal hypertension screening if advanced fibrosis/cirrhosis

Common Pitfalls to Avoid

1. Don't rely on ALT/AST alone—normal transaminases do NOT exclude advanced fibrosis 1, 2
2. Don't skip the two-step approach—elastography without prior FIB-4 leads to unnecessary referrals 1, 2
3. Don't forget alcohol quantification—underreporting is common; use validated questionnaires 2
4. Don't overlook cardiovascular risk—this kills more MASLD patients than liver disease 4, 6
5. Age matters for FIB-4—adjust interpretation in elderly and young patients 2

Strength of Evidence

The 2024 EASL-EASD-EASO guidelines 1, 2 represent the most current, high-quality consensus recommendations with strong agreement (92-100% consensus) on the sequential non-invasive testing approach. The stepwise FIB-4-then-elastography strategy is a strong recommendation with Level 2 evidence, balancing diagnostic accuracy with healthcare resource utilization.